Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

(Unaudited)

Table of Contents

For the six months ended June 30, 2025 and 2024

	Page
Condensed Interim Consolidated Financial Statements	
Condensed Interim Consolidated Statements of Financial Position	4
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss	5
Condensed Interim Consolidated Statements of Changes in Equity (Deficiency)	6
Condensed Interim Consolidated Statements of Cash Flows	7
Notes to the Condensed Interim Consolidated Financial Statements	8 -22

Notice of No Auditor Review of Condensed Interim Consolidated Financial Statements

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor, McGovern, Hurley, Cunningham, LLP, has not performed a review of these unaudited condensed interim consolidated financial statements, in accordance with standards established by the Institute of Chartered Professional Accountants for a review of condensed interim consolidated financial statements by an entity's auditor.

BacTech Environmental Corporation August 27, 2025

Condensed Interim Consolidated Statements of Financial Position

(Unaudited, expressed in Canadian dollars, unless otherwise stated)

	As at June 30 2025	As at December 31 2024
	\$	\$
Assets		
Current assets		
Cash	456,163	5,361
Sales taxes receivable	18,049	7,036
Investments, marketable securities (note 22)	651,836	755,000
Prepaids and deposits	11,851	17,010
Total current assets	1,137,899	784,407
Non-Current assets		
Land (note 15)	980,564	980,564
Guarantee and other deposits	95,839	101,080
Total non-current assets	1,076,403	1,081,644
Total assets	2,214,302	1,866,051
Liabilities Current liabilities		
Accounts payable and accrued liabilities (notes 6 and 7)	2,909,816	3,017,447
Government assistance (note 20)	60,000	60,000
Payable to Aquila Resources Inc. (note 5)	161,294	161,294
Debentures (note 8a)	100,000	100,000
Convertible debentures (note 8b)	1,353,637	1,275,857
Total current liabilities	4,584,747	4,614,598
Liabilities related to abandoned subsidiary (note 19)	180,647	180,647
Total liabilities	4,765,394	4,795,245
Shareholders' deficiency		
Share capital (note 9)	11,356,429	10,494,623
Option reserve (note 11)	1,047,767	1,084,631
Warrant reserve (note 10)	356,181	233,731
Equity conversions feature (note 8b)	188,838	188,838
Deficit	(15,500,307)	(14,931,017)
Total shareholders' deficiency	(2,551,092)	(2,929,194)
Total liabilities and shareholders' deficiency	2,214,302	1,866,051

Nature of Operations and Going Concern (*note 1***)**

Commitments and Contingencies (note 18)

Subsequent Event- (Note 23)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Approved by the Board

Signed: "Ross Orr" Signed: "Jay Richardson"

Director Director

BacTech Environmental CorporationCondensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Unaudited, expressed in Canadian dollars, unless otherwise stated)

	Three months ended June 30		ded Six months June 3	
	2025	2024	2025	2024
	\$	\$	\$	\$
Expenses				
Operating and administrative costs (note 13)	335,453	422,340	626,554	795,541
Finance charges (note 14)	49,939	75,237	111,215	145,497
Project expenditures	30,000	117	30,781	31,903
Total expense	415,392	497,694	768,550	972,941
Net loss for the period before the undernoted	(415,392)	(497,694)	(768,550)	(972,941)
Loss from other items				
Loss from change in fair value of marketable securities	16,768	-	(100,232)	-
Net loss and comprehensive loss for the period	(398,624)	(497,694)	(868,782)	(972,941)
Basic and diluted loss per share (note 12)	0.00	(0.005)	(0.005)	(0.005)
Weighted average number of common shares				
outstanding (note 12)	210,372,055	193,035,834	202,880,344	193,035,834

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

BacTech Environmental Corporation Condensed Interim Consolidated Statements of Changes in Equity (Deficiency) (Unaudited, expressed in Canadian dollars, unless otherwise stated)

	Share Capital	Share Capital	Option Reserve	Warrant Reserve	Equity Conversion Reserve	Deficit	Deficit
	#	\$	\$	\$	\$	\$	\$
Balance, December 31. 2023	193,035,834	10,494,623	960,901	1,205,090	188,838	(15,066,268)	(2,216,816)
Expired warrants	-	-	-	(948,330)	-	948,330	-
Share based payments (note 11)	-	-	115,740	-	-	_	115,740
Net loss for the period	-	-	-	-	-	(972,941)	(972,941)
Balance, June 30, 2024	193,035,834	10,494,623	1,076,641	256,760	188,838	(15,090,879)	(3,074,017)
Expired warrants	-	-	-	(23,029)	-	23,029	-
Share based payments (note 11)	-	-	7,990	-	-	_	7,990
Net loss for the period	-	-	-	-	-	136,833	136,833
Balance, December 31, 2024	193,035,834	10,494,623	1,084,631	233,731	188,838	(14,931,017)	(2,929,194)
Shares issued pursuant to private placement (note 9 (i))	25,334,000	885,487	-	381,213	-	-	1,266,700
Share issue costs (9 (i))	-	(23,681)	-	3,865	-	-	(19,816)
Expired warrants	-	-	(36,864)	-	-	36,864	-
Expired options	-	-	-	(262,628)	-	262,628	-
Net loss for the period	-	-	-	-	-	(868,782)	(868,782)
Balance, June 30, 2025	218,369,834	11,356,429	1,047,767	356,181	188,838	(15,500,307)	(2,551,092)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Cash Flows

(Unaudited, expressed in Canadian dollars, unless otherwise stated)

	Six months ended June 30, 2025	Six months ended June 30, 2024
	\$	\$
Cash flow from operating activities		
Cash paid to suppliers, employees and consultants	(796,082)	(72,335)
Net cash used in operating activities	(796,082)	(72,335)
Cash flow from financing activities		
Gross proceeds from private placements	1,266,700	-
Share issue costs from financings	(19,816)	-
Net cash provided by financing activities	1,246,884	-
Increase in cash	450,802	(72,335)
Cash, beginning of the period	5,361	73,199
Cash, end of the period	456,163	864

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

1. Nature of Operations and Going Concern

BacTech Environmental Corporation (the "Company" or "BacTech") was incorporated by REBgold Corporation ("REBgold" and formerly BacTech Mining Corporation) on October 5, 2010 under the Canada Business Corporations Act. The Company has the primary rights and know-how to use a bioleaching technology. The technology utilizes bacteria to extract precious and base metals and has been traditionally used to treat difficult-to-treat sulphide ores and concentrates.

The business plan for the Company is to apply bioleaching technology to abatement and reclamation projects to remove the harmful elements such as arsenic and sulphur from the environment, where this can be assisted by a positive cash flow from metal recovery. Examples of metals which could potentially be extracted include gold, silver, cobalt, nickel, copper, uranium and zinc. The Company's head office is located at 37 King Street East, Suite 409, Toronto, Ontario, M5C 1E9.

The accompanying condensed interim consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has no sources of recurring revenue, has realized net loss of \$868,782 during the six months ended June 30, 2025, has working capital deficit of \$3,446,848 at June 30, 2025, is dependent on financings to fund its operations. The ability of the Company to continue as a going concern is dependent upon the continuing financial support of shareholders or other investors, obtaining new financing on commercial terms acceptable to the Company to enable it to monetize its intellectual property assets, and upon attaining profitable operations once such assets can be monetized, all of which outcomes are materially uncertain and which, taken together, cast significant and substantial doubt over the ability of the Company to continue as a going concern. These condensed interim consolidated financial statements do not include any adjustments to the carrying values of the Company's assets, liabilities, and expenses and the related statement of financial position and statement of loss classifications that would be necessary if the going concern assumption were inappropriate. Such adjustments have not been quantified by management but could be material.

The Company funded its operations for the six months ended June 30, 2025 from existing cash reserves and a private placement for gross proceeds of \$1,226,700. The Company does not have sufficient cash reserves to fund its administrative costs and fund any project development initiatives for the coming twelve months, nor to repay its liabilities to trade creditors and debt holders. These matters represent material uncertainties that cast significant and substantial doubt about the Company's ability to continue as a going concern. Management is actively involved in identifying reclamation and abatement ventures amenable to the application of the Company's technology license, and is seeking new equity or debt financing to enable it to service the Company's liabilities and its ongoing administrative costs. There can be no assurance that the Company will be successful in these initiatives.

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

2. Basis of Consolidation and Presentation

Statement of Compliance with International Financial Accounting Standards ("IFRS")

Statement of Compliance

These condensed interim consolidated financial statements of the Company have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting ("IAS 34") as issued by the International Accounting Standards Board ("IASB") and using the accounting policies the Company reported in Note 2 and 3 in its audited annual consolidated financial statements for the year ended December 31, 2024. These condensed interim consolidated financial statements do not include all of the information required for full annual financial statements.

The accounting policies have been applied consistently to all periods presented in these condensed interim consolidated financial statements.

These condensed interim consolidated financial statements were authorized for issuance by the Board of Directors of the Company on August 27, 2025.

Basis of Preparation and Presentation

These condensed interim consolidated financial statements have been prepared on a historical cost basis except for the revaluation of certain financial instruments. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

The condensed interim consolidated financial statements are presented in Canadian dollars, which is also the Company's functional currency.

Basis of Consolidation

These condensed interim consolidated financial statements comprise the financial statements of the Company and its subsidiaries, Empresa Minera Ambiental BacTech S.A. incorporated in Bolivia, and BacTechVerde S.A.S incorporated in Ecuador. Accounting policies of the subsidiary have been changed where necessary to ensure consistency with the policies adopted by the Company.

Intercompany balances and transactions, including unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the condensed interim consolidated financial statements.

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

3. Material Accounting Policies

Critical Judgements and Estimation Uncertainties

The preparation of consolidated financial statements in conformity with IFRS requires the Company's management to make judgments, estimates and assumptions about future events that affect the amounts reported in the consolidated financial statements and related notes to the financial statements. Although these estimates are based on management's best knowledge of the amount, event or actions, actual results may differ from those estimates and these differences could be material.

The areas which require management to make significant judgments, estimates and assumptions in determining carrying values include, but are not limited to:

- Assets' carrying values and impairment charges:
- Impairment of deferred assessment and evaluation costs:
- Estimation of decommissioning and restoration costs and the timing of expenditure:
- Taxes, income taxes and deferred taxes:
- Share-Based Payments:
- Convertible Debentures:
- Commitments and Contingencies:
- Investments Shares and warrants of a public company:
- Research and Development:

4. Adoption and Future Changes in Accounting Standards

Certain pronouncements were issued by the IASB that are mandatory for accounting years on or after January 1, 2025 or later years. Many are not applicable or do not have significant impact on the Company and have been excluded.

In addition, the following standards have been issued by IASB and the Company is currently assessing the impact on the consolidated financial statements. These have not been adopted for the current period.

- Amendments to the Classification and Measurement of Financial Instruments (IFRS 9 and IFRS 7) with mandatory application of the standard in Condensed Interim reporting periods beginning on or after January 1, 2026.
- *IFRS 18 Presentation and Disclosure in Financial Statements* with mandatory application of the standard in the Condensed Interim reporting periods beginning on or after January 1, 2027.

5. Payable to Aquila Resources Inc.

REBgold completed a divisive reorganization by way of a Plan of Arrangement whereby a subsidiary, BacTech, was granted rights and interests in REBgold's existing and proposed tailings remediation. During the year ended December 31, 2013, REBgold amalgamated with Aquila Resources Inc. The balance is unsecured, non-interest bearing, and is due on demand.

6. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following as at:

	June 30	December 31
	2025	2024
	\$	\$
Trade payables	690,641	825,520
Accrued liabilities - other	2,219,175	2,191,927
Total	2,909,816	3,017,447

Included in accrued liabilities are certain liabilities totaling approximately \$792,154 that due to the length of time passed since the Company recorded them, management considers this uncollectable by the vendor. Management believes that there will be no impact on the business of the Company and accounts payable amounts will not be pursued by vendors nor will the Company pay these amounts. See note 7 for related party amounts included in accrued liabilities and trade payables.

Included in accrued liabilities is a demand loan of \$120,000 from an investor with fixed interest of \$20,000 which is accrued and reported under finance charges.

7. Related Party Transactions

In accordance with IAS 24, key management personnel are those having authority and responsibility for planning, directing and controlling the activities of the Company directly or indirectly, including any directors (executive and non-executive) of the Company. Related party transactions are in the normal course of business and are recorded at the amount agreed to between the parties.

Related party transactions consist of the following for the six months ended:

	June 30 2025 \$	June 30	
		2024 \$	
Salaries and management fees	222,250	222,250	
Share based payments	-	52,493	
Total	222,250	274,743	

Included in accounts payable and accrued liabilities is \$644,225 due to related parties at June 30, 2024 (December, 2024 - \$748,200). Refer to Note 9 – Capital for equity transactions with related parties. These amounts are unsecured, non-interest bearing and due on demand.

Notes to the Condensed Interim Consolidated Financial Statements For the six months ended June 30, 2025 and 2024

8. Debentures

(a) Debentures with Bonus Interest

Between April 19, 2017 and June 26, 2017, BacTech completed three tranches of a debenture financing for gross proceeds of \$445,000 and accompanied by the issuance of 1,780,000 common shares which are included as a bonus equity interest. The debentures have a 2-year term and pay 12% interest annually. The debenture included a 20% common stock bonus interest payment (issued at \$0.05 per share). For example, a \$10,000 debenture would be accompanied by 40,000 common shares of BacTech, subject to a 4-month restriction on resale from the date of closing.

The fair value of the bonus shares was determined by reference to the trading prices of the Company's common shares on the date the tranches were closed. The Company issued 1,780,000 common shares in connection with the debenture financing with an aggregate value of \$70,100. Transaction costs included a cash commission of \$8,400 and 84,000 broker warrants that have expired unexercised during the year ended December 31, 2019. Each broker warrant entitled the holder to purchase one common share at an exercise price of \$0.10 for a period of 12 months and were valued at \$350. The aggregate transaction cost, which included the bonus shares, cash commission and warrants, was recorded against the debenture and was being amortized over the life of the debenture and shown as accretion expense.

For the debenture holders that have reached their maturity date in fiscal 2019, the Company requested that the debenture holders extend the term of the debentures. In consideration of the extension of the maturity date, the Company offered to issue a common share purchase warrant allowing the debenture holders to purchase a common share of the Company at five cents for a period of three years. In fiscal 2020, \$20,000 of the debenture holders formally accepted the terms to extend the maturity date. A total of 496,000 warrants were issued at a value of \$6,072. These costs were amortized through accretion expenses and loss of modification of debenture.

On August 20, 2020, an arm's length debenture holder agreed to convert \$87,500 face value of debentures and the related accrued interest at \$0.05 per share. This transaction resulted in the issuance of 3,083,352 common shares and reduced \$154,168 in principal of the debenture and interest owing.

On April 19, 2021, an arm's length debenture holder agreed to convert \$25,000 face value of debentures and the \$9,000 of accrued interest. This transaction resulted in the issuance of 680,000 common shares and a 37,400 loss on redemption of debenture.

On November 1, 2021, the Company settled the repayment of certain debentures through the issuance of 3,564,822 common shares and 3,564,822 warrants to settle the outstanding debenture face value of \$232,500 and accumulated interest \$123,982.

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

As of June 30, 2025 and December 31, 2024, the remaining debenture is past its maturity date and is currently due on demand. As such, it is presented as a current liability in the statement of financial position.

	June 30 2025	December 31 2024
	\$	\$
Face value of debentures	445,000	445,000
Transactions costs allocated to debentures	(78,850)	(78,850)
Cost of extension of maturity date	(42,878)	(42,878)
Loss on modification of debenture	14,409	14,409
Accumulated accretion	107,319	107,319
Redemptions and settlements	(345,000)	(345,000)
Balance	100,000	100,000

During the six months ended June 30, 2025, interest expense of \$6,000 (2024 – \$6,000) was recorded under finance charges in the statement of loss.

(b) Convertible Debentures

On April 21, 2022, the Company completed a \$1,000,000 convertible debenture issuance with an existing strategic investor. The terms of the convertible debentures allow for a conversion at \$0.15 per share at the option of the holder, an annual interest rate of 8% and a term of 18 months.

On March 14, 2023, BacTech closed a \$250,0000 convertible debenture with the same investor who previously completed a \$1.0 million convertible debenture. On September 1, 2023 the same investor advanced an additional \$150,000. The convertible debenture terms are the same as the prior debenture, but now with the full principal balance of \$1.4 million was not due until September 4, 2024. The debenture extension was agreed to by the debenture holder for a 1% royalty of the Company's Ecuador project, defined and described in the same manner as the royalty as announced for the May 5, 2022, and February 28, 2022, private placements, making a total of 2% NSR having been granted on the Project.

Transaction costs included a cash commission of \$60,000 and 399,999 broker warrants. Each broker warrant entitled the holder to purchase one common share at an exercise price of \$0.15 for a year of 24 months and were valued at \$29,100 (see Note 10). The fair value of the convertible debenture at the time of issue was calculated assuming an effective interest rate of 20% based on market analysis of peer companies. In addition, the fair value of the convertible debenture conversion option was determined to be \$202,134 with an allocated cost of capital of \$13,296. The aggregate transaction cost, which included the cash commission and warrants, was recorded against the debenture and is being amortized over the life of the debenture and shown as accretion expense.

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

	June 30 2025 \$	December 31 2024 \$
Face value of debentures	1,400,000	1,400,000
Valuation allocated to equity conversion	(202,134)	(202,134)
Transaction costs allocated to debentures	(75,805)	(75,805)
Gain on modification	(260,891)	(260,891)
Accretion	492,467	414,687
Balance	1,353,637	1,275,857

The debenture holder agreed to extend the maturity date of the total debenture until September 30, 2025. Since the maturity is within one year, the debenture is presented as a current liability in the statement of financial position.

9. Share Capital

Authorized share capital is made up of unlimited common shares without par value:

(i) On March 4, 2025, March 28, 2025 and May 30, 2025, BacTech completed three tranches of a private placement financing for \$1,266,700 in gross proceeds through the issuance of 25,334,000 Units.

Each Unit consists of one common share of BacTech and one, two-year warrant exercisable at \$0.10. The warrant includes an acceleration clause. In the event the common shares trade at or above \$0.20 for 10 consecutive trading days, as indicated on the CSE Exchange, the Company shall have give notice by way of a press release that the Warrants' expiry date will expire 20 trading days thereafter.

The fair value of the 25,334,000 common share purchase warrants issued in this placement was estimated at \$381,213 using the Black-Sholes option pricing model. Share issue costs incurred on this private placement were cash costs of \$19,816 and the issue of 256,000 broker warrants valued at \$3,865 using the Black-Sholes option pricing model

Certain officers and directors participated in the private placement for gross proceeds of \$74,200 through issuance of 1,484,000 Units.

For the six months ended June 30, 2025 and 2024

10. Warrant Reserve

The movements in the number and estimated fair value of outstanding broker warrants and share purchase warrants are as follows:

	Six months ended June 30, 2025		Year ended December 31, 2	
	Number Outstanding	Weighte d Average Exercise Price \$	Number Outstanding	Weighted Average Exercise Price \$
Balance, beginning of period	15,674,290	0.12	28,100,304	0.19
Issued	25,590,000	0.10	-	-
Expired	(11,358,500)	0.12	(12,426,014)	0.27
Balance, end of period	29,905,790	0.10	15,674,290	0.12

The exercise price, expiry date, and the fair value assigned to warrants issued and outstanding as at June 30, 2025 are as follows:

	Weighted Average Exercise Price	Grant Date Fair Value	Warrants Outstanding	Remaining Contractual Life
Expiry Date	\$	\$		(yr)
May 30, 2027	0.10	185,837	12,200,000	1.92
May 30, 2027	0.10	2,437	160,000	1.92
March 28,2027	0.10	96,691	6,500,000	1.74
March 4, 2027	0.10	98,685	6,634,000	1.68
March 4, 2027	0.10	1,428	96,000	1.68
Dec 18, 2025	0.12	86,200	3,837,750	0.47
Dec 18, 2025	0.12	11,010	478,040	0.47
	0.10	482,288	29,905,790	1.62

The fair values of the warrants issued during the six months ended June 30, 2025 and year ended December 31, 2024 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	2025	2024
Risk free interest rate	2.50 to 2.59%	3.75 to 3.99%
Expected dividend yield	Nil	Nil
Exercise price	\$0.10	\$0.08 to \$0.12
Share price	\$0.045	\$0.07 to \$0.08
Expected volatility	115 to 118%	85% to 96%
Expected life	2 years	2 years

Option pricing models require the input of subjective assumptions regarding the expected volatility, which is calculated based on the historical price of the Company's common shares. Changes in assumptions can materially affect the estimate of fair value, and therefore, use of Black-Scholes option pricing model may not provide a realistic measure of the fair value of the Company's warrants at the date of issue.

11. Stock Options

The Company has a stock option plan (the "Plan"), under which the Company may grant options to directors, officers, employees, and third party service providers. Under the terms of the Plan that was reapproved by the shareholders on September 16, 2021, the Company is authorized to issue a maximum of 10% of the issued and outstanding shares.

The purpose of the Plan is to attract, retain and motivate directors, officers, and certain third party service providers by providing them with the opportunity to acquire a proprietary interest in the Company and benefit from its growth. The options granted under the Plan are non-assignable, have a term of up to five years and vest over a period of up to three years from the date of issue.

	Six months ended June 30, 2025		Year ended December 31, 2024	
		Weighted Average Exercise		Weighted Average Exercise
	Number Outstanding	Price \$	Number Outstanding	Price \$
Balance, beginning of period	15,150,000	0.11	12,950,000	0.11
Granted	-	-	2,200,000	0.10
Expired	(1,000,000)	0.15	-	-
Balance, end of period	14,150,000	0.10	15,150,000	0.11

Options to purchase common shares outstanding at June 30, 2025 carry exercise prices and remaining terms to maturity as follows:

Expiry Date	Weighted Average Exercise Price \$	Grant Date Fair Value \$	Number of Options Outstanding	Number of Options Exercisable	Remaining Weighted Average Contractual Life (yr.)
March 26, 2026	0.12	217,120	2,200,000	2,200,000	0.74
August 10, 2026	0.15	68,940	200,000	200,000	1.11
September 16, 2026	0.15	102,840	1,100,000	1,100,000	1.21
January 4, 2027	0.15	151,578	1,100,000	1,100,000	1.52
December 12, 2027	0.10	271,534	3,600,000	3,600,000	2.45
March 13, 2028	0.10	103,812	1,250,000	1,250,000	2.70
November 27, 2029	0.10	7,990	300,000	300,000	4.41
May 31, 2029	0.10	90,058	1,900,000	1,900,000	3.92
August 20, 2030	0.05	74,900	2,500,000	2,500,000	5.14
	0.10	1,088,772	14,150,000	14,150,000	2.73

For the six months ended, June 30, 2025, the Company granted no new options. The Company recognized share-based payment expense of \$Nil for the six months ending June 30, 2025. For the year ended December 31, 2024, the Company granted 2,200,000 options with a life of 5 years and vesting immediately. The Company recognized share-based payment expense of \$123,730 for the year ended December 31, 2024.

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

The fair values of the options issued during the year ended December 31, 2024 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

2024

	2024
Risk free interest rate	3.09% - 3.88%
Expected dividend yield	Nil
Exercise price	\$0.10
Share price	\$0.02 - \$0.05
Expected volatility	163% - 183%
Expected life	5 years

Option pricing models require the input of subjective assumptions regarding the expected volatility, which is calculated based on the historical price of the Company's common shares. Changes in assumptions can materially affect the estimate of fair value, and therefore, use of Black-Scholes option pricing model may not provide a realistic measure of the fair value of the Company's warrants at the date of issue.

12. Loss per Share

The calculation of basic and diluted loss per share for the six months ended June 30, 2025 includes a net loss attributable to common shareholders of \$868,782 (2024 - \$972,941) and the weighted average number of common shares outstanding of 202,880,344 (2024 –193,035,834). For the three months ended June 30, 2025 the calculation of basic and diluted loss per share is based on loss attributable to common shareholders of \$398,624 (2024 – \$497,694) and the weighted average number of common shares outstanding of 210,372,055 (2024 – 193,035,834). The calculation of basic and diluted loss per share did not include the effect of share purchase options and warrants outstanding as they would be anti-dilutive.

13. Operating and Administrative

Operating and administrative expense consists of the following:

	Three months ended June 30		Six months ended June 30	
	2025	2024	2025	2024
	\$	\$	\$	\$
Salaries and management fees (note 7)	129,741	147,052	271,099	292,664
Share based payments (note 11)	-	97,145	_	115,740
Professional fees	117,620	39,141	190,860	79,805
Shareholder information and filing fees	29,921	119,006	72,014	263,744
Travel	37,850	7,250	53,369	19,475
General office expenses	23,845	13,111	41,315	27,432
Foreign exchange gain	(3,524)	(365)	(2,103)	(3,319)
Total	335,453	422,340	626,554	795,541

14. Finance Charges

Finance charges consist of the following:

	Three months ended June 30		Six months ended June 30	
	2025	2025	2025	2024
	\$	\$	\$	\$
Interest and bank charges	172	5,247	3,152	5,517
Debenture interest	3,000	31,000	30,283	62,000
Accretion expense	46,767	38,990	77,780	77,980
Total	49,939	75,237	111,215	145,497

15. Land Purchase

The Company acquired a parcel of land for its proposed processing plant in Tenguel, Ecuador which closed in September 2022.

16. Financial Risk Factors

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit risk

The Company has no significant concentration of credit risk arising from operations. Management believes that the credit risk concentration with respect to sales tax receivable is remote.

Liquidity risk

As at June 30, 2025, the Company had a cash balance of \$456,163 (December 31, 2024 - \$5,361) against current liabilities of \$4,584,747 (December 31, 2024 - \$4,614,598). The Company does not have sufficient cash reserves to fund its administrative costs and fund any project development initiatives for the coming year, and to repay its liabilities to trade creditors and debt holders. Management is actively involved in identifying reclamation ventures amenable to the application of the Company's technology and in seeking new equity financing to enable it to service the Company's liabilities and its ongoing administrative costs. There can be no assurance that the Company will be successful in these initiatives.

While the multiple debt conversions and forgiveness have substantially improved the Company's Statement of Financial Position, its liquidity remains at a parlous low level and it continues to incur costs that will require continued success in additional financings.

Market risk

(a) Interest rate risk

The Company has cash earning interest at a low variable interest rate and debentures bearing interest at 8% and 12% per annum. The Company's current policy is to invest excess cash in investment-grade short-term deposit certificates issued by its banking institutions..

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

(b) Foreign currency risk

The Company's functional currency is the Canadian dollar. Major purchases are transacted in Canadian dollars. The Company funds certain operations and administrative expenses using United States dollars. Management believes the foreign exchange risk derived from currency conversions is negligible and therefore does not hedge its foreign exchange risk.

(c) Price risk

The Company is not exposed to price risk with respect to commodity prices because the Company is not a producing entity.

Classification of financial instruments

Financial assets included in the statement of financial position are as follows.

	June 30		Dec	December 31	
		2025		2024	
Financial assets at amortized cost:					
Cash	\$	456,163	\$	5,391	
Financial assets at fair value:					
Investments, marketable securities	\$	651,836	\$	755,000	

Financial liabilities included in the statement of financial position are as follows.

	June 30	De	ecember 31
	2025		2024
Financial liabilities at amortized cost:			
Payable to Aquila Resources Inc.	\$ 161,294	\$	161,294
Accounts payable and accrued liabilities	\$ 2,909,816	\$	2,955,047
Government assistance	\$ 60,000	\$	60,000
Debentures	\$ 1,500,000	\$	1,500,000

Fair value

The condensed interim consolidated statements of financial position carrying amounts for cash, receivables and trade payables, approximate fair value due to their short-term nature.

The following provides a description of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which the fair value is observable:

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Notes to the Condensed Interim Consolidated Financial Statements For the six months ended June 30, 2025 and 2024

As at June 30, 2025 the Company has financial instruments measured at fair value include the Silver Crown shares that are classified as Level 1 and the Silver Crown warrants that are classified at Level 2, within the fair value hierarchy.

17. Capital Management

The Company defines capital as shareholders' equity. The Company's objective when managing its capital is to restore its deficit to a positive balance in order to provide an adequate return to shareholders by maintaining a sufficient level of funds, in order to support the acquisition, assessment and evaluation, and development of mineral reclamation properties. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business.

The Company is currently in the early stages of evaluation and assessment of projects; as such, the Company is dependent on external financing to fund its activities. In order to carry out the assessment and evaluation of the projects and pay for administrative costs, the Company will spend its existing working capital and raise additional amounts as needed. The Company will continue to assess new properties and seek to acquire an interest in additional properties, if it feels there is sufficient geologic or economic potential, and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company does not have externally imposed capital requirements. The Company's capital management objectives, policies and processes have remained unchanged during the six months ended June 30, 2025 and year ended December 31, 2024.

The Company is not subject to any capital requirements imposed by a lending institution or regulatory body, other than of the Canadian Securities Exchange ("CSE"). The impact of any violation of CSE policy is not known and is ultimately dependent on the discretion of the CSE.

18. Commitments and Contingencies

Management contract

The Company currently has employment agreements with the provision of termination and change of control benefits with the three officers of the Company. The agreements for each officer provides that in the event that their employment is terminated by the Company other than for cause then the officer shall be entitled to a lump sum payment amount up to twelve months base salary plus 1 month salary for each year of service (\$651,500) to a maximum of thirty-six months base salary. If a change of control were to occur, the officer would be entitled up to two years of compensation (\$1,330,000). As a triggering event has not taken place, the contingent payments have not been reflected in these condensed interim consolidated financial statements.

Environmental matters

The Company's exploration activities are subject to various laws and regulations governing the protection of the environment. These laws and regulations are continually changing and generally becoming more restrictive. The Company conducts its operations so as to protect public health and the environment and believes its operations are materially in compliance with all applicable laws and regulations. The Company has made, and expects to make in the future, expenditures to comply with such laws and regulations (*Note* 22).

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

19. Liabilities related to abandoned Subsidiary

On May 24, 2016, BacTech announced that its 98% owned Bolivian subsidiary Empresa Minera Ambiental BacTech S.A" ("EMABSA"), had signed an Association Contract with Corporación Minera de Bolivi" ("COMIBOL"), the state mining company of Bolivia. On September 15, 2016, the Bolivian government approved and ratified the agreement.

On September 9, 2019, the Company announced that it would not proceed with the reclamation of the Telamayu tailings project in Bolivia. The Company has abandoned the Bolivian subsidiary which is inactive. Management believes that there will be no impact on the business of the Company and accounts payable amounts will not be pursued by vendors beyond their recourse against the abandoned subsidiary.

The liabilities have been included in the Company's balance sheet from the abandoned subsidiary in the amount of \$180,647 for the six months ended June 30, 2025 (\$180,647 -December 31, 2024).

20. Government assistance

Canada Business Emergency Account

In fiscal 2020, the Company received a \$60,000 emergency business loan under the federal government Canada Business Emergency Account ("CEBA") initiative. The company did not repay the balance prior to January 19, 2024, and as such the loan was renewed for a three year term with a fixed condensed interim rate of interest of 5%. No repayments have been made as of June 30, 2025.

21. Proceeds from Intellectual Property

BacTech is in the process of developing a "zero-waste" preliminary patent and aims to generate a portfolio of saleable products from re-treatment of tailings near Sudbury, Canada. BacTech has received \$75,000 as a deposit against a potential sale of a 10% interest in it's "Zero Waste" technology. As no agreement has yet been signed this \$75,000 is included in accrued liabilities.

The Company is currently in the research phase for its "zero-waste" preliminary patent and all related expenditures are recorded as research expenses under operating and administrative costs

22. Royalty Purchase Agreement with Silver Crown Royalties Inc.

On October 28, 2024, BacTech announced the completion of the Royalty Purchase Agreement for the sale of a portion of its anticipated condensed interim silver production with Silver Crown Royalties Inc. ("Silver Crown"). The silver is expected to be a byproduct of its planned bioleach gold production in Tenguel, Ecuador. On November 21, 2024 BacTech announced the closing of the transaction.

Under the terms of the agreement, Silver Crown acquires a royalty on BacTech's planned bioleaching facility in Tenguel, Ecuador (the "Project"). The 10 year term for the annual royalty equates to the cash equivalent of the greater of (i) 90% of the silver processed at the facility, or (ii) minimum annual payment of 35,000 ounces of silver. Royalty payments become due on a quarterly basis after one year from the commencement of commercial operation of the Project.

In exchange, Silver Crown will pay \$4,000,000 in common shares, issued in three (3) tranches:

• The first tranche, received upon closing of this transaction, includes 100,000 common shares issued at a deemed value of \$10.00 share plus 100,000 share purchase warrants exercisable at \$16.00 for 3 years from closing;

Notes to the Condensed Interim Consolidated Financial Statements

For the six months ended June 30, 2025 and 2024

- The second installment of 100,000 common shares issued at a deemed value of \$10.00 will be received upon BacTech successfully securing the Project financing for the building of the Tenguel plant; and
- The final instalment of 200,000 common shares issued at a deemed value of \$10.00 will be received once commercial production begins at the Project.

According to the terms of the contract there is no obligation to pay any royalty until the facility in Tenguel, Ecuador is built and commissioned for operations. The future contingent installments of shares to be received upon successfully completing future milestones have not been included in the financial statements as it is not certain these milestones will be reached.

The value of the 100,000 Silver Crown shares and warrants at the time the transaction closed in October 2024 had a fair market value of \$774,000 for the shares and \$59,000 for the warrants. As at December 31, 2024, the estimated fair market value of the 100,000 Silver Crown shares were \$708,000 and the warrants were \$47,000 and unrealized a loss of \$78,000 from the decrease in fair value at year end.

During the six months ended June 30, 2025 the Company sold 500 Silver Crown common shares for gross proceeds of \$3,250. As at June 30, 2025, the estimated fair market value of the remaining 99,500 Silver Crown shares were \$631,825 and the warrants were \$20,000, which translates to an unrealized a loss of \$100,039 and realized loss of \$193 as at June 30, 2025.

The fair values of the warrant for the six months ended June 30, 2025 and year ended December 31, 2024 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	2025	2024
Risk free interest rate	2.47 to 2.75%	2.87% to 3.35%
Expected dividend yield	Nil	Nil
Exercise price	16.00	\$16.00
Share price	\$6.14 to \$6.25	\$7.08 to \$7.10
Expected volatility	40%	40% to 41%
Expected life	3 years or less	3 years or less

23. Subsequent Event

At the date of this report there is no subsequent event to report.